Preview this article 1 min Personalis shareholders will receive $16.25 per share. The deal is expected to close in late 2026 ...

On July 1, Freedom Capital initiated coverage of Tempus AI, Inc. (NASDAQ:TEM) with a Hold rating. The firm gave a $59 price target on the shares.

The AI in pathology market is witnessing strong growth, driven by the increasing adoption of digital pathology, rising cancer incidence, and the growing demand for faster and more accurate diagnostic ...

Key Points Interested in Tempus AI, Inc.? Here are five stocks we like better. Tempus AI plans to acquire Personalis to ...

According to MarketsandMarkets™, the AI in Drug Discovery Market is projected to reach USD 17.56 billion by 2031 from USD ...

According to MarketsandMarketstm, the AI in Drug Discovery Market is projected to reach USD 17.56 billion by 2031 from USD 5.09 billion in 2026, at a CAGR of 28.1% during the forecast ...

According to BCC Research, AI is helping medical plastics companies reduce production costs, improve product consistency and accelerate innovation for medical devices and healthcare ...

Tempus AI is positioning itself at the intersection of healthcare, artificial intelligence, and data analytics. As more patient information flows through its platform, the company gains additional ...

AI can be added to legacy motion control systems in three phases with minimal disruption: data collection via edge gateways, non-interfering anomaly detection and supervisory control integration.

Seasoned manufacturing professionals know the assets that make their products – the assembly robots, CNC machines, and conveyor belts – are just as important as the final products themselves. These ...

Caris Life Sciences proprietary WES/WTS/WGS technology and massive data advantage underpin its leadership in oncology ...